These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 33577365

  • 1. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
    Khriguian J, Tsui JMG, Vaughan R, Kucharczyk MJ, Nabid A, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Mohiuddin M, Niazi T.
    J Urol; 2021 Jun; 205(6):1648-1654. PubMed ID: 33577365
    [Abstract] [Full Text] [Related]

  • 2. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S, Lloret M, Naranjo A, Déniz F, Chesa N, Domínguez C, Lara PC.
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Oct; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 5. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.
    N Engl J Med; 2001 Sep 27; 345(13):948-55. PubMed ID: 11575286
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".
    de la Taille A.
    World J Urol; 2014 Dec 27; 32(6):1625-6. PubMed ID: 24413818
    [No Abstract] [Full Text] [Related]

  • 8. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.
    J Urol; 2006 Aug 27; 176(2):520-5. PubMed ID: 16813881
    [Abstract] [Full Text] [Related]

  • 9. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR.
    Cancer; 2003 Feb 01; 97(3 Suppl):789-95. PubMed ID: 12548577
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T, Campbell J, Bryant C, Lynch W.
    Cancer; 1998 Oct 15; 83(8):1561-6. PubMed ID: 9781950
    [Abstract] [Full Text] [Related]

  • 13. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
    Washino S, Hirai M, Saito K, Kobayashi Y, Arai Y, Miyagawa T.
    Low Urin Tract Symptoms; 2018 Jan 15; 10(1):57-63. PubMed ID: 27943566
    [Abstract] [Full Text] [Related]

  • 14. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.
    Urology; 2010 May 15; 75(5):1131-7. PubMed ID: 20163839
    [Abstract] [Full Text] [Related]

  • 15. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
    Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HALT Prostate Cancer Study Group.
    N Engl J Med; 2009 Aug 20; 361(8):745-55. PubMed ID: 19671656
    [Abstract] [Full Text] [Related]

  • 16. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.
    Cussenot O, Cornu JN, Drouin SJ, Mozer P, Egrot C, Vaessen C, Haab F, Bitker MO, Rouprêt M.
    World J Urol; 2014 Apr 20; 32(2):545-50. PubMed ID: 24166289
    [Abstract] [Full Text] [Related]

  • 17. [Total androgen blockade].
    Namiki M, Mizokami A.
    Nihon Rinsho; 2002 Dec 20; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract] [Full Text] [Related]

  • 18. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R, Pahalajani G, Agarwal A, Zippe C.
    Asian J Androl; 2007 Mar 20; 9(2):253-8. PubMed ID: 17334592
    [Abstract] [Full Text] [Related]

  • 19. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
    Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F, Galì A, Frisina N, Melloni D.
    Eur Urol; 2005 May 20; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
    [Abstract] [Full Text] [Related]

  • 20. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ.
    Eur J Cancer; 2015 Aug 20; 51(12):1555-69. PubMed ID: 26048455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.